Cargando…

Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis

BACKGROUND/AIMS: Data on the efficacy and safety of the adalimumab biosimilar Exemptia are limited. METHODS: Patients with moderate-to-severe active steroid-refractory ulcerative colitis (UC) treated at Dayanand Medical College and Hospital, India were offered cyclosporine A, biologicals or biosimil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Midha, Vandana, Mahajan, Ramit, Mehta, Varun, Narang, Vikram, Singh, Arshdeep, Kaur, Kirandeep, Sood, Ajit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Association for the Study of Intestinal Diseases 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797276/ https://www.ncbi.nlm.nih.gov/pubmed/29422802 http://dx.doi.org/10.5217/ir.2018.16.1.83

Ejemplares similares

Endoscopy for assessment of mucosal healing in ulcerative colitis: time bound or response guided?
por: Sood, Ajit, et al.
Publicado: (2022)

Efficacy of fecal microbiota therapy in steroid dependent ulcerative colitis: a real world intention-to-treat analysis
por: Sood, Ajit, et al.
Publicado: (2019)

Incidental benefits after fecal microbiota transplant for ulcerative colitis
por: Mahajan, Ramit, et al.
Publicado: (2020)

Symptomatic isolated terminal ileal ulcers: etiology and clinical significance
por: Mehta, Varun, et al.
Publicado: (2017)

Association of endoscopic and histological remission with clinical course in patients of ulcerative colitis
por: Narang, Vikram, et al.
Publicado: (2018)

Fecal Microbiota Transplantation for Ulcerative Colitis: An Evolving Therapy
por: Sood, Ajit, et al.
Publicado: (2020)

Trends of inflammatory bowel disease at a tertiary care center in northern India
por: Sood, Ajit, et al.
Publicado: (2021)

Exclusive enteral nutrition for induction of remission in anti-tumor necrosis factor refractory adult Crohn’s disease: the Indian experience
por: Sood, Ajit, et al.
Publicado: (2020)

Maintaining infliximab induced clinical remission with azathioprine and 5-aminosalicylates in acute severe steroid-refractory ulcerative colitis has lower cost and high efficacy (MIRACLE): a multicenter study
por: Mahajan, Ramit, et al.
Publicado: (2022)

A simple phenotypic classification for celiac disease
por: Sood, Ajit, et al.
Publicado: (2018)

Impact of "Sambhav" Program (Financial Assistance and Counselor Services) on Hepatitis C Pegylated Interferon Alpha Treatment Initiation in India
por: Sood, Ajit, et al.
Publicado: (2018)

Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up
por: Chandra, Alok, et al.
Publicado: (2019)

Clinical profile and outcomes of opioid abuse gastroenteropathy: an underdiagnosed disease entity
por: Mahajan, Ramit, et al.
Publicado: (2020)

A Case of Isotretinoin Therapy-Refractory Folliculitis Decalvans Treated Successfully with Biosimilar Adalimumab (Exemptia)
por: Shireen, Furtado, et al.
Publicado: (2018)

An open-label randomised pilot trial on safety of wheat variety C273 in patients with adult celiac disease
por: Grover, Jasmine, et al.
Publicado: (2020)

Clinical spectrum of elderly-onset inflammatory bowel disease in India
por: Gupta, Yogesh Kumar, et al.
Publicado: (2023)

A prospective, randomized, double‐blind, multicentre, parallel‐group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC‐3197) and adalimumab (Humira) in patients with rheumatoid arthritis
por: Jani, Rajendrakumar H., et al.
Publicado: (2015)

Colitis and Crohn’s Foundation (India): a first nationwide inflammatory bowel disease registry
por: Sood, Ajit, et al.
Publicado: (2021)

Inflammatory bowel disease (IBD)-disk accurately predicts the daily life burden and parallels disease activity in patients with IBD
por: Singh, Arshdeep, et al.
Publicado: (2023)

Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease
por: Sood, Ajit, et al.
Publicado: (2020)

Adalimumab biosimilars in the therapy of Crohn´s disease and ulcerative colitis: Prospective multicentric clinical monitoring
por: Wasserbauer, Martin, et al.
Publicado: (2022)

Impact of Corona Virus Disease-19 (COVID-19) pandemic on gastrointestinal disorders
por: Baryah, Amol Nanak Singh, et al.
Publicado: (2020)

Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab
por: Freeman, Hugh J
Publicado: (2013)

Low prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease in India
por: Singh, Arshdeep, et al.
Publicado: (2023)

Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis
por: Kim, Jae Hyun, et al.
Publicado: (2016)

Variable Immunogenic Potential of Wheat: Prospective for Selection of Innocuous Varieties for Celiac Disease Patients via in vitro Approach
por: Grover, Jasmine, et al.
Publicado: (2019)

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
por: Suzuki, Yasuo, et al.
Publicado: (2013)

Inflammatory Bowel Disease and X (Formerly Twitter) Influencers: Who Are They and What Do They Say?
por: Garg, Ayushi, et al.
Publicado: (2023)

An Investigation of Genome-Wide Studies Reported Susceptibility Loci for Ulcerative Colitis Shows Limited Replication in North Indians
por: Juyal, Garima, et al.
Publicado: (2011)

AVT02: An Adalimumab Biosimilar
por: Kang, Connie
Publicado: (2022)

Low hygiene and exposure to infections may be associated with increased risk for ulcerative colitis in a North Indian population
por: Sood, Ajit, et al.
Publicado: (2014)

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
por: Jiang, Yijia, et al.
Publicado: (2023)

Real‐life Tolerability and Effectiveness of Adalimumab Biosimilar in Ankylosing Spondylitis: the Adalimumab Biosimilar Patient Registry Data
por: Kapoor, Sanjiv, et al.
Publicado: (2019)

Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis
por: Suzuki, Yasuo, et al.
Publicado: (2017)

Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis
por: Schultz, Bob G, et al.
Publicado: (2021)

Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study
por: Barberio, Brigida, et al.
Publicado: (2020)

Correction to: AVT02: An Adalimumab Biosimilar
por: Kang, Connie
Publicado: (2022)

Navigating adalimumab biosimilars: an expert opinion
por: Abitbol, Vered, et al.
Publicado: (2023)

Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis
por: Yokomizo, Lauren, et al.
Publicado: (2016)

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2pni9re4k1obvsfs8026el4mut